In a filing, Crinetics Pharmaceuticals Inc revealed its Chief Med and Dev Officer Pizzuti Dana unloaded Company’s shares for reported $86021.0 on Mar 19 ’25. In the deal valued at $34.20 per share,2,515 shares were sold. As a result of this transaction, Pizzuti Dana now holds 72,233 shares worth roughly $2.6 million.
Then, Knight Jeff E. sold 7,162 shares, generating $244,964 in total proceeds. Upon selling the shares at $34.20, the Chief Operating Officer now owns 87,491 shares.
Before that, Betz Stephen F. sold 5,770 shares. Crinetics Pharmaceuticals Inc shares valued at $197,353 were divested by the Chief Scientific Officer at a price of $34.20 per share. As a result of the transaction, Betz Stephen F. now holds 108,588 shares, worth roughly $3.9 million.
TD Cowen initiated its Crinetics Pharmaceuticals Inc [CRNX] rating to a Buy in a research note published recently. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in early February with a ‘”a Peer perform”‘ rating. Jefferies also remained covering CRNX and has increased its forecast on January 22, 2025 with a “Buy” recommendation from previously “Hold” rating. Citigroup started covering the stock on March 06, 2024. It rated CRNX as “a Buy”.
Price Performance Review of CRNX
On Monday, Crinetics Pharmaceuticals Inc [NASDAQ:CRNX] saw its stock jump 4.42% to $35.94. Over the last five days, the stock has gained 2.10%. Crinetics Pharmaceuticals Inc shares have fallen nearly -29.71% since the year began. Nevertheless, the stocks have fallen -20.99% over the past one year. While a 52-week high of $62.53 was reached on 01/03/25, a 52-week low of $31.84 was recorded on 02/25/25. SMA at 50 days reached $36.30, while 200 days put it at $48.58.
Levels Of Support And Resistance For CRNX Stock
The 24-hour chart illustrates a support level at 34.88, which if violated will result in even more drops to 33.81. On the upside, there is a resistance level at 36.56. A further resistance level may holdings at 37.17. The Relative Strength Index (RSI) on the 14-day chart is 52.35, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.40, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 4.88%. Stochastics %K at 64.10% indicates the stock is a holding.
How much short interest is there in Crinetics Pharmaceuticals Inc?
A steep rise in short interest was recorded in Crinetics Pharmaceuticals Inc stocks on 2025-02-28, growing by 0.73 million shares to a total of 8.11 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 7.38 million shares. There was a rise of 8.98%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 16, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $50 price target.
